Publication | Closed Access

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly

MedicineSingle-agent GemcitabinePharmacologyClinical TrialsMetronomic TherapyBronchial NeoplasmPharmacotherapyCancer TreatmentOncologyLung CancerMolecular Oncology